Advanced Basal Cell Carcinoma: Navigating an Evolving Therapeutic Landscape: A Care Team Forum

78-21-358-VL-003 BCC CTF Web Thumbnail
Proprietary Educational Format:

Activity Overview

Therapeutic options for advanced basal cell carcinoma (BCC) have been transformed by the introduction of Hedgehog pathway inhibitors (HPIs) and the emergence of immunotherapy. Led by a multidisciplinary expert panel, this activity uniquely features an experienced patient sharing key insights from their treatment journey. The discussion focuses on the role and place of HPIs and PD-1 inhibitors in advanced BCC and provides professional guidance on managing class-specific toxicities, including immune-mediated adverse events.

0.75 CE Credit(s)
Expires: April 8, 2022

Target Audience

This activity is designed to meet the educational needs of dermatology and oncology physicians who diagnose and manage patients with advanced basal cell carcinoma (BCC).

Learning Objectives

Upon successful completion of this education activity, participants should be better able to:

  • Apply current data to the appropriate selection of Hedgehog inhibitors in advanced basal cell carcinoma (BCC)
  • Evaluate the role and place of immunotherapy in managing patients with advanced BCC

 

Activity Faculty

Hamid, Omid

Omid Hamid, MD

Chief, Translational Research and Immunotherapy
Director, Melanoma Center and Phase I Immuno-Oncology Program
The Angeles Clinic and Research Institute
Los Angeles, CA
M. Lacotour Headshot

Mario Lacouture, MD

Director, Oncodermatology Program
Professor of Dermatology
Memorial Sloan Kettering Cancer Center
New York City, NY

Michelle Offner Headshot

Michelle Offner, RN, MSN, ACNP-BC

Nurse Practitioner, Medical Oncology (Cutaneous Malignancies)
The Angeles Clinic and Research Institute
Los Angeles, CA